Friess Associates’s CareDx CDNA Stock Holding History

Friess Associates’s Portfolio CDNA Stock Details CDNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-28,270	Closed	-$1.79M	–	92
2021 Q3	$1.79M	Buy	+28,270	New	+$2.15M	0.75%	64
2020 Q4	–	Sell	-54,125	Closed	-$2.05M	–	99
2020 Q3	$2.05M	Buy	54,125 +7,508	+16%	+$253K	0.18%	80
2020 Q2	$1.65M	Buy	+46,617	New	+$1.33M	0.15%	85
2019 Q4	–	Sell	-233,482	Closed	-$5.28M	–	112
2019 Q3	$5.28M	Buy	233,482 +12,939	+6%	+$358K	0.41%	66
2019 Q2	$7.94M	Buy	220,543 +17,845	+9%	+$571K	0.58%	67
2019 Q1	$6.39M	Sell	202,698 -4,297	-2%	-$125K	0.47%	70
2018 Q4	$5.2M	Buy	206,995 +84,195	+69%	+$2.16M	0.44%	71
2018 Q3	$3.54M	Buy	+122,800	New	+$2.3M	0.25%	85
2018 Q2	–	Sell	-37,373	Closed	-$298K	–	111
2018 Q1	$298K	Sell	37,373 -109,043	-74%	-$672K	0.02%	101
2017 Q4	$1.07M	Buy	+146,416	New	+$913K	0.09%	100

Other funds holding CDNA

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

FAM

Fred Alger Management New York $22.8B AUM 64.63% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

Friess Associates's CDNA Position: Q4 2021 in Review

Friess Associates sold out of CareDx (CDNA) in Q4 2021, closing a stake of 28,270 shares — an estimated $1.79M sold.

Friess Associates first reported a position in CDNA in Q4 2017 and held it in 10 quarters. The position peaked at $7.94M in Q2 2019. 224 funds tracked by Wall St. Rank hold CDNA as of Q4 2021.

Friess Associates reported no remaining CareDx position as of Q4 2021 after selling out during the quarter.
Friess Associates sold 28,270 CareDx shares in Q4 2021, an estimated $1.79M.
Friess Associates first reported a position in CareDx in Q4 2017 and held it in 10 quarters.
Friess Associates's CareDx position peaked at $7.94M in Q2 2019.
224 funds tracked by Wall St. Rank held CareDx as of Q4 2021.

Based on Friess Associates's 13F filing for Q4 2021, filed 11 Feb 2022.